Company: NCEL
Filing Date: 2025-02-10
Form Type: F-3
Source: 0001213900-25-011823
Chunk: 14

Company: NewcelX Ltd.
Filing Date: 2025-02-10
Form: F-3
Chunk 14
---
 that gain marketing approval. |

| ● | International expansion of Kadimastem’s business exposes it to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States, within Israel, the EU and Japan. |

| ● | Kadimastem’s market is subject to intense competition, which may result in others commercializing products before or more successfully. |

You should consider carefully the summary of risk factors described above and the full risks described under the caption “Item 3. Key Information - D. Risk Factors” in our annual report on Form 20-F for the year ended December 31, 2023, or the 2023 Annual Report, which is incorporated by reference in this prospectus, before deciding whether to invest in the Common Shares. Closings of Private Placement Financing Transaction On December 4, 2024, we entered into the December SPA, with a certain accredited investor, the Selling Shareholder. Pursuant to the terms of the December SPA, we agreed to issue and sell to the Selling Shareholder, in a private placement offering, up to 322,580 Common Shares at a purchase price of $3.10 per Common Share for aggregate gross proceeds of $1 million, subject to shareholder approval. The initial closing of the offering closed in the amount of $500,000, with the approval of certain items in NLS’s extraordinary general meeting on January 7, 2025, resulting in an issuance of 161,290 Common Shares to the Selling Shareholder. Pursuant to the terms of the December SPA, the Company agreed that on or before January 9, 2025, the Company would authorize and reserve sufficient Common Shares to satisfy the anti-dilution and ratchet rights of the Selling Shareholder under the October Debt SPA entered into on October 9, 2024, after giving effect to the conversion price reduction of the preferred shares as a result of the Dilutive Issuances (as defined in the October SPA) caused by the Company entering into the December SPA. On or before January 7, 2025, we authorized and reserved sufficient Common Shares to satisfy the anti-dilution and ratchet rights of the Selling Shareholder under the October Debt SPA. We further issued to the Selling Shareholder in accordance therewith the entire amount of ratchet securities following the approval of certain items in NLS’s extraordinary general meeting on January 7, 2025, as follows: (i) 408,871 preferred